Q&A: Providing Services to Children with ADHD & Disabilities During the COVID-19 Outbreak
The CHADD Public Policy Committee is sharing the document Questions and Answers on Providing Services to Children with Disabilities during the Coronavirus Disease 2019 Outbreak. This document addresses questions on IDEA and Section 504 educational plans, along with meeting the needs of children with disabilities who may also be affected by COVID-19. The Centers for…
Read MoreCHADD Responds to FDA Request for Comments on ADHD Medications
The US Food and Drug Administration recently asked for comments on making stimulant medications more difficult to abuse and how those changes could affect the millions of people who include medication in their ADHD treatment plans. The Federal Register notice states that stimulant medications can be open to abuse but that reformulating them can potentially…
Read MoreCharter Schools: Discipline and Implications for Students with ADHD
At eight years old, Michael was diagnosed with ADHD. The traditional city school he attended declined to evaluate him to determine eligibility for special education and related services because his grades were above average. Instead, the school provided Michael with minimal accommodations through a 504 plan. As the years progressed, Michael’s grades began to decline,…
Read MoreNew Research Suggests Untreated ADHD Reduces Life Expectancy
CHADD and Russell A. Barkley, Ph.D., Partner Announce New Findings Lanham, Md. (Jan. 8, 2019)— The message is clear. Treatment for attention-deficit/hyperactivity disorder (ADHD), along with the related health risks it poses, has the possibility of adding an average of nine to 13 years to the lifespan of children and adults diagnosed with ADHD. This…
Read MoreCHADD Position Statement on Controlled Substances Measures
CHADD has become aware of state and local policies, including legislation and regulations, intended to address the misuse of opioids, but which may have unintended consequences for children and adults prescribed FDA-approved medications to treat attention deficit hyperactivity disorder (ADHD). Read the full statement.
Read MoreCHADD’s Position on Patient Access to ADHD Medications
Medication Access Principles: CHADD ascribes to the following principles regarding access to medications indicated to treat attention deficit / hyperactivity disorder (ADHD). Medication is recognized by the scientific community as a primary treatment to effectively reduce the core symptoms of ADHD.[1] Given the stigma associated with ADHD and common misconceptions about treating the disorder, individuals…
Read MoreAmerican Health Care Act
The House of Representatives had been preparing to vote on the American Health Care Act (AHCA), which would repeal significant portions of the Affordable Care Act (ACA or “Obamacare”) and replace them with alternative coverage policies. At this time, the House is not moving forward with a vote on the AHCA. Read our full report.
Read MoreHealth Insurance Coverage and ADHD
In September 2016, CHADD conducted a survey about health insurance coverage and attention deficit hyperactivity disorder (ADHD) in the United States. More than 1500 people from all 50 states and Washington, D.C. took part in the online survey and answered 15 anonymous questions about their personal experiences seeking access to services and medications for their,…
Read More